|
1
|
Oldham RK and Dillman RO: Principles of
Cancer Biotherapy. Springer Science and Business Media; New York,
NY: 2009, View Article : Google Scholar
|
|
2
|
Canavan TP and Doshi NR: Cervical cancer.
Am Fam Physician. 61:1369–1376. 2000.PubMed/NCBI
|
|
3
|
Litjens RJ, Hopman AH, van de Vijver KK,
Ramaekers FC, Kruitwagen RF and Kruse AJ: Molecular biomarkers in
cervical cancer diagnosis: A critical appraisal. Expert Opin Med
Diagn. 7:365–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pras E, Willemse PH, Canrinus AA, de
Bruijn HW, Sluiter WJ, ten Hoor KA, Aalders JG, Szabo BG and de
Vries EG: Serum squamous cell carcinoma antigen and CYFRA 21-1 in
cervical cancer treatment. Int J Radiat Oncol Biol Phys. 52:23–32.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaarenstroom K, Bonfrer J, Korse C, Kenter
G and Kenemans P: Value of Cyfra 21-1, TPA, and SCC-Ag in
predicting extracervical disease and prognosis in cervical cancer.
Anticancer Res. 17:2955–2958. 1997.PubMed/NCBI
|
|
6
|
Borras G, Molina R, Xercavins J, Ballesta
A and Iglesias J: Tumor antigens CA 19.9, CA 125, and CEA in
carcinoma of the uterine cervix. Gynecol Oncol. 57:205–211. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Battaglia F, Scambia G, Panici PB,
Castelli M, Ferrandina G, Foti E, Amoroso M, D'Andrea G and Mancuso
S: Immunosuppressive acidic protein (IAP) and squamous cell
carcinoma antigen (SCC) in patients with cervical cancer. Gynecol
Oncol. 53:176–182. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki Y, Nakano T, Ohno T, Abe A, Morita
S and Tsujii H: Serum CYFRA 21-1 in cervical cancer patients
treated with radiation therapy. J Cancer Res Clin Oncol.
126:332–336. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forni F, Ferrandina G, Deodato F, Macchia
G, Morganti AG, Smaniotto D, Luzi S, D'Agostino G, Valentini V,
Cellini N, et al: Squamous cell carcinoma antigen in follow-up of
cervical cancer treated with radiotherapy: Evaluation of
cost-effectiveness. Int J Radiat Oncol Biol Phys. 69:1145–1149.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
FIGO Committee on Gynecologic Oncology, .
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Apgar BS, Zoschnick L and Wright TC Jr:
The 2001 Bethesda system terminology. Am Fam Physician.
68:1992–1998. 2003.PubMed/NCBI
|
|
12
|
The UniProt Consortium: UniProt: A
worldwide hub of protein knowledge. Nucleic Acids Res.
47:D506–D515. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mi H, Muruganujan A, Huang X, Ebert D,
Mills C, Guo X and Thomas PD: Protocol update for large-scale
genome and gene function analysis with the PANTHER classification
system (v.14.0). Nat Protoc. 14:703–721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heberle H, Meirelles GV, da Silva FR,
Telles GP and Minghim R: InteractiVenn: A web-based tool for the
analysis of sets through Venn diagrams. BMC Bioinformatics.
16:1692015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maranga IO, Hampson L, Oliver AW, Gamal A,
Gichangi P, Opiyo A, Holland CM and Hampson IN: Analysis of factors
contributing to the low survival of cervical cancer patients
undergoing radiotherapy in Kenya. PLoS One. 8:e784112013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zampronha Rde A, Freitas-Junior R, Murta
EF, Michelin MA, Barbaresco AA, Adad SJ, de Oliveira AM, Rassi AB
and Oton GJ: Human papillomavirus types 16 and 18 and the prognosis
of patients with stage I cervical cancer. Clinics (Sao Paulo).
68:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Akawi ZJ, Al-Hindawi FK and Bashir NA:
Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and
breast cancer patients. Neuro Endocrinol Lett. 29:482–484.
2008.PubMed/NCBI
|
|
18
|
Yamaguchi N, Yamamura Y, Koyama K, Ohtsuji
E, Imanishi J and Ashihara T: Characterization of new human
pancreatic cancer cell lines which propagate in a protein-free
chemically defined medium. Cancer Res. 50:7008–7014.
1990.PubMed/NCBI
|
|
19
|
Lee HB, Yoo OJ, Ham JS and Lee MH: Serum
α1-antitrypsin in patients with hepatocellular carcinoma. Clin Chim
Acta. 206:225–230. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pérez-Holanda S, Blanco I, Menéndez M and
Rodrigo L: Serum concentration of alpha-1 antitrypsin is
significantly higher in colorectal cancer patients than in healthy
controls. BMC Cancer. 14:3552014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Akawi ZJ, Abu-Awad AM, Sharara AM and
Khader YS: The importance of alpha-1 antitrypsin (α1-AT) and
neopterin serum levels in the evaluation of nonsmall cell lung and
prostate cancer patients. Neuro Endocrinol Lett. 31:113–116.
2010.PubMed/NCBI
|
|
22
|
Thompson DK, Haddow JE, Smith DE and
Ritchie RF: Elevated serum acute phase protein levels as predictors
of disseminated breast cancer. Cancer. 51:2100–2104. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Akawi ZJ, Abu-Awad AM and Khouri NA:
Alpha-1 antitrypsin blood levels as indicator for the efficacy of
cancer treatment. World J Oncol. 4:83–86. 2013.PubMed/NCBI
|
|
24
|
Nilsson R, Jain M, Madhusudhan N, Sheppard
NG, Strittmatter L, Kampf C, Huang J, Asplund A and Mootha VK:
Metabolic enzyme expression highlights a key role for MTHFD2 and
the mitochondrial folate pathway in cancer. Nat Commun. 5:31282014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang
H, Wang J, Lin TG, Zhang K, Chu P, et al: Human mitochondrial
pyrroline-5-carboxylate reductase 1 promotes invasiveness and
impacts survival in breast cancers. Carcinogenesis. 38:519–531.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ou R, Zhang X, Cai J, Shao X, Lv M, Qiu W,
Xuan X, Liu J, Li Z and Xu Y: Downregulation of
pyrroline-5-carboxylate reductase-2 induces the autophagy of
melanoma cells via AMPK/mTOR pathway. Tumor Biol. 37:6485–6491.
2016. View Article : Google Scholar
|
|
27
|
Liu W, Hancock CN, Fischer JW, Harman M
and Phang JM: Proline biosynthesis augments tumor cell growth and
aerobic glycolysis: Involvement of pyridine nucleotides. Sci Rep.
5:172062015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Ingeniis J, Ratnikov B, Richardson AD,
Scott DA, Aza-Blanc P, De SK, Kazanov M, Pellecchia M, Ronai Z,
Osterman AL and Smith JW: Functional specialization in proline
biosynthesis of melanoma. PLoS One. 7:e451902012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu W, Le A, Hancock C, Lane AN, Dang CV,
Fan TW and Phang JM: Reprogramming of proline and glutamine
metabolism contributes to the proliferative and metabolic responses
regulated by oncogenic transcription factor c-MYC. Proc Natl Acad
Sci. 109:8983–8988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu L, Liu J, Dai S, Wang X, Wu S, Wang J,
Huang L, Xiao X and He D: Reduced transthyretin expression in sera
of lung cancer. Cancer Sci. 98:1617–1624. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang D, Liang H, Mao X, Liu W, Li M and
Qiu S: Changes of transthyretin and clusterin after androgen
ablation therapy and correlation with prostate cancer malignancy.
Transl Oncol. 5:124–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shimura T, Shibata M, Gonda K, Okayama H,
Saito M, Momma T, Ohki S and Kono K: Serum transthyretin level is
associated with prognosis of patients with gastric cancer. J Surg
Res. 227:145–150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lorkova L, Pospisilova J, Lacheta J,
Leahomschi S, Zivny J, Cibula D, Zivny J and Petrak J: Decreased
concentrations of retinol-binding protein 4 in sera of epithelial
ovarian cancer patients: A potential biomarker identified by
proteomics. Oncol Rep. 27:318–324. 2012.PubMed/NCBI
|
|
34
|
Ehmann M, Felix K, Hartmann D, Schnölzer
M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW and Friess H:
Identification of potential markers for the detection of pancreatic
cancer through comparative serum protein expression profiling.
Pancreas. 34:205–214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu L, Wang J, Liu B, Dai S, Wang X, Chen
J, Huang L, Xiao X and He D: Serum levels of variants of
transthyretin down-regulation in cholangiocarcinoma. J Cell
Biochem. 104:745–755. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fatima I, Sadaf S, Musharraf SG, Hashmi N
and Akhtar MW: CD5 molecule-like and transthyretin as putative
biomarkers of chronic myeloid leukemia-an insight from the
proteomic analysis of human plasma. Sci Rep. 7:409432017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mählck CG and Grankvist K: Plasma
prealbumin in women with epithelial ovarian carcinoma. Gynecol
Obstet Invest. 37:135–140. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhattacharyya T, Nicholls SJ, Topol EJ,
Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, et
al: Relationship of paraoxonase 1 (PON1) gene polymorphisms and
functional activity with systemic oxidative stress and
cardiovascular risk. JAMA. 299:1265–1276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cockerill GW, Rye KA, Gamble JR, Vadas MA
and Barter PJ: High-density lipoproteins inhibit cytokine-induced
expression of endothelial cell adhesion molecules. Arterioscler
Thromb Vasc Biol. 15:1987–1994. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Souza JA, Vindis C, Nègre-Salvayre A,
Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ
and Kontush A: Small, dense HDL 3 particles attenuate apoptosis in
endothelial cells: Pivotal role of apolipoprotein A-I. J Cell Mol
Med. 14:608–620. 2010.PubMed/NCBI
|
|
41
|
Su F, Kozak KR, Imaizumi S, Gao F, Amneus
MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, et al:
Apolipoprotein AI (apoA-I) and apoA-I mimetic peptides inhibit
tumor development in a mouse model of ovarian cancer. Proc Natl
Acad Sci. 107:19997–20002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zamanian-Daryoush M, Lindner D, Tallant
TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D,
Parsons-Wingerter P, Rayman P, et al: The cardioprotective protein
apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol
Chem. 288:21237–21252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zamanian-Daryoush M and DiDonato JA:
Apolipoprotein AI and cancer. Front Pharmacol. 6:2652015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kozak KR, Su F, Whitelegge JP, Faull K,
Reddy S and Farias-Eisner R: Characterization of serum biomarkers
for detection of early-stage ovarian cancer. Proteomics.
5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Takaishi S and Wang TC: Gene expression
profiling in a mouse model of Helicobacter-induced gastric cancer.
Cancer Sci. 98:284–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hamrita B, Ben Nasr H, Gabbouj S,
Bouaouina N, Chouchane L and Chahed K: Apolipoprotein A1 −75 G/A
and +83 C/T polymorphisms: Susceptibility and prognostic
implications in breast cancer. Mol Biol Rep. 38:1637–1643. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yamamoto N and Homma S: Vitamin D3 binding
protein (group-specific component) is a precursor for the
macrophage-activating signal factor from
lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci.
88:8539–8543. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Binder R, Kress A, Kan G, Herrmann K and
Kirschfink M: Neutrophil priming by cytokines and vitamin D binding
protein (Gc-globulin): Impact on C5a-mediated chemotaxis,
degranulation and respiratory burst. Mol Immunol. 36:885–892. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang HT, Tian EB, Chen YL, Deng HT and
Wang QT: Proteomic analysis for finding serum pathogenic factors
and potential biomarkers in multiple myeloma. Chin Med J.
128:1108–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Layne TM, Weinstein SJ, Graubard BI, Ma X,
Mayne ST and Albanes D: Serum 25-hydroxyvitamin D, vitamin D
binding protein, and prostate cancer risk in black men. Cancer.
123:2698–2704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mondul AM, Weinstein SJ, Moy KA, Männistö
S and Albanes D: Vitamin D-binding protein, circulating vitamin D
and risk of renal cell carcinoma. Int J Cancer. 134:2699–2706.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Anic GM, Weinstein SJ, Mondul AM, Männistö
S and Albanes D: Serum vitamin D, vitamin D binding protein, and
risk of colorectal cancer. PLoS One. 9:e1029662014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mondul AM, Weinstein SJ, Virtamo J and
Albanes D: Influence of vitamin D binding protein on the
association between circulating vitamin D and risk of bladder
cancer. Br J Cancer. 107:1589–1594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Laszlo GS, Alonzo TA, Gudgeon CJ,
Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch
BA, Gamis AS, et al: Multimerin-1 (MMRN1) as novel adverse marker
in pediatric acute myeloid leukemia: A Report from the Children's
Oncology Group. Clin Cancer Res. 21:3187–3195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Human Protein Atlas. https://www.proteinatlas.org/ENSG00000138722-MMRN1/pathology/stomach+cancerFebruary
6–2020
|
|
56
|
Human Protein Atlas. https://www.proteinatlas.org/ENSG00000138722-MMRN1/pathology/renal+cancerFebruary
6–2020
|
|
57
|
Chokchaichamnankit D, Watcharatanyatip K,
Subhasitanont P, Weeraphan C, Keeratichamroen S, Sritana N,
Kantathavorn N, Diskul-Na-Ayudthaya P, Saharat K, Chantaraamporn J,
et al: Urinary biomarkers for the diagnosis of cervical cancer by
quantitative label-free mass spectrometry analysis. Oncol Lett.
17:5453–5468. 2019.PubMed/NCBI
|
